PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
61 hedge funds and large institutions have $95.8M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
40% less call options, than puts
Call options by funds: $97K | Put options by funds: $162K
Holders
61
Holding in Top 10
–
Calls
$97K
Puts
$162K
Top Buyers
| 1 | +$1.44M | |
| 2 | +$933K | |
| 3 | +$818K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$681K |
| 5 |
O
OrbiMed
New York
|
+$551K |
Top Sellers
| 1 | -$3.1M | |
| 2 | -$1.6M | |
| 3 | -$692K | |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$339K |
| 5 |
E
Ergoteles
New York
|
-$184K |